MARKET

LRMR

LRMR

Larimar Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.80
-0.48
-4.26%
Closed 16:00 08/05 EDT
OPEN
10.59
PREV CLOSE
11.28
HIGH
11.00
LOW
10.59
VOLUME
6.61K
TURNOVER
--
52 WEEK HIGH
20.28
52 WEEK LOW
7.43
MARKET CAP
165.44M
P/E (TTM)
-0.0781
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LRMR stock price target is 0.7800 with a high estimate of 0.7800 and a low estimate of 0.7800.

EPS

LRMR News

More
Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
BALA CYNWYD, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Exe
GlobeNewswire · 2d ago
Larimar Therapeutics poised to nab European Orphan Drug tag for CTI-1601 in FA
The European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion backing Orphan Drug status for Larimar Therapeutics's
seekingalpha · 07/28 17:50
Larimar Therapeutics Announces Positive Opinion On Orphan Drug Designation Received From European Medicines Agency For CTI-1601 For The Treatment Of Friedreich's Ataxia
BALA CYNWYD, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that
Benzinga · 07/28 12:05
Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia
BALA CYNWYD, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the European Medicines Agency (EMA) Committee
GlobeNewswire · 07/28 12:00
Larimar Therapeutics advances early-stage study of CTI-1601 in genetic disorder
Larimar Therapeutics (NASDAQ:LRMR) has dosed patients in the third cohort of Phase 1 trial of CTI-1601 in Friedreich’s ataxia. The will evaluate the safety
seekingalpha · 07/21 02:18
Larimar Therapeutics Announces Dosing Of Patients In Third Cohort Of Phase 1 SAD Trial Of CTI-1601 For Treatment Of Friedreich's Ataxia
Benzinga · 07/20 20:15
Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia
BALA CYNWYD, Pa., July 20, 2020 -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare.
GlobeNewswire · 07/20 20:15
Larimar Therapeutics (Formerly Zafgen) 8-K Shows Securities Purchase Deal For Private Placement Of 6.105M Shares, Pre-Funded Warrants For ~628K Shares At $11.8/Share, Warrant
Benzinga · 06/02 11:58

Industry

Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About LRMR

Larimar Therapeutics Inc., formerly Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for complex rare diseases using its cell penetrating peptide technology platform. The Company’s protein replacement therapy platform provides disease-modifying therapies that intends to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that have no treatments available. The Company’s lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN) into the mitochondria of patients with Friedreich’s ataxia (FA). CTI-1601 is in Phase I clinical program. The Company intends to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
More

Webull offers kinds of Larimar Therapeutics Inc stock information, including NASDAQ:LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.